Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program

Pentixapharm Holding AG (Frankfurt Prime Standard: PTP), a clinical-stage biotech developing novel radiopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...
The Manila Times

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A ...

Exilby® Receives First European Marketing Authorization as VERTANICAL Prepares UK Submission for its First-in-Class Non-Opioid Treatment for Chronic Low Back Pain

VERTANICAL today announced that Exilby® (VER-01) has received marketing authorization in Germany for the treatment of chronic low back pain with a radicular (neuropathic) component.
The Manila Times

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve ...
Business Wire

Anova Announces First Patient Enrolled to Phase 1/2a Study of DB107 for the Treatment of High-Grade Gliomas

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two patients in the ...